Survival rates in patients with advanced liver cancer are not improved by the mTOR inhibitor everolimus, the EVOLVE-1 clinical trial suggests
The study followed 546 adults with advanced hepatocellular carcinoma (HCC) who were intolerant to or had experienced disease progression with sorafenib. They were randomly assigned to everolimus 7.5mg/day or placebo, with best supportive care.
Median overall survival rates did not differ between everolimus and placebo, at 7.6 versus 7.3 months. The results “extend the list of failed phase III studies in advanced HCC, highlighting the challenge of developing effective therapies for this cancer”, the investigators remark in
 Zhu AX et al. JAMA 2014;312(1):57-67.